A Study of Homoeopathic Medicine WITHANIA SOMNIFERA with Computer Simulation and Clinical Evaluation of the same in the Management of GOITRE.

An In Silico Analysis and Randomized Clinical Trial of Homoeopathic Medicine WITHANIA SOMNIFERA in GOITRE. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086489

Enrollment

Registered

2025-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E049- Nontoxic goiter, unspecified

Interventions

Intervention1: Withania Somnifera: Withania Somnifera 6C in 40 size globules 3 globules thrice a day for 5 weeks Control Intervention1: Homoeopathic Constitutional Medicine: Constitutional Medicine gi

Eligibility

Inclusion criteria

Inclusion criteria: i. Patients between 18 and 65 years of age. ii. Patients with positive ultrasonography with evidence of goiter.

Exclusion criteria

Exclusion criteria: i. TSH less than or equal to 0.05 mIU/mL greater than or equal to 30 mIU/mL ii. Evidence of malignant changes in ultrasonography [TIRADS 4 and 5]. iii. Patients with complications, such as signs and symptoms of excessive mechanical obstruction and pressure effects on adjacent structures. iv. Patients with immune deficiency diseases. v. Patients with any severe systemic illness, like uncontrolled diabetes mellitus, malignant hypertension, other malignancies, etc. vi. Immunocompromised patients. vii. Pregnant and lactating mothers.

Design outcomes

Primary

Measure	Time frame
1. In silico study: Action of the phytochemical compounds in Withania somnifera on the target protein of the thyroid gland will be assessed. 2. Clinical study A] Changes in the ORDIL score will be assessed to monitor the changes in quality of life of the patient. B] Changes in the size of the goitre will be assessed through thyroid ultrasonography. Timepoint: 1. In silico study Duration- 1 month 2. Clinical study A] ORDIL Score assessed as follows at a regular 4 weeks interval over a 4 months period. B] Thyroid Ultrasonography will be asssesed before and after treatment that is after 4 months.	—

Measure

Time frame

1. In silico study: Action of the phytochemical compounds in Withania somnifera on the target protein of the thyroid gland will be assessed. 2. Clinical study A] Changes in the ORDIL score will be assessed to monitor the changes in quality of life of the patient. B] Changes in the size of the goitre will be assessed through thyroid ultrasonography. Timepoint: 1. In silico study Duration- 1 month 2. Clinical study A] ORDIL Score assessed as follows at a regular 4 weeks interval over a 4 months period. B] Thyroid Ultrasonography will be asssesed before and after treatment that is after 4 months.

—

Secondary

Measure	Time frame
Comparison of Therapeutic effectiveness of Withania Somnifera and Homoeopathic constitutional medicines among the groups.Timepoint: After 1 year [ after completion of the study ]	—

Countries

India

Contacts

Public ContactDr Lakshmi Babu

Government Homoeopathic Medical College Karaparamba Kozhikode

drjayakishan@gmail.com9446529775

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026